Personalizing therapy for multidrug resistant TB: The potential of Rapid Whole Genome Sequencing

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 1, 2016, Pages 1-3

  Bryant, Josephine M ^a   Lipman, Marc ^b   Breuer, Judith ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

DST; Genomics; Sequencing; Tuberculosis; WGS

Indexed keywords

ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; DRUG EFFECT; EDITORIAL; GENE SEQUENCE; GROWTH RATE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; BACTERIUM IDENTIFICATION; CLASSIFICATION; GENE LOCUS; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; BACTERIAL TYPING TECHNIQUES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENETIC LOCI; GENOME, BACTERIAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; PRECISION MEDICINE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84954372169     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2016.1116385     Document Type: Editorial

References (25)

1. WHO. Global Tuberculosis Report 2014. Geneva: World Health Organization; 2014
2. Pietersen E, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383(9924):1230-1239
3. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. Br Med J. 1948;2(4588):1009-1015
4. Outhred AC, et al. Added value of wholegenome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother. 2015;70(4):1198-1202
5. Melchionda V, et al. Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Eur Respir J. 2013;42(4):1148-1150
6. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9(10):2026-2030
7. Lawn SD, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13(4):349-361
8. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995;8 (4):496-514
9. Barnard M, et al. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med. 2012;186(12):1298-1305
10. Van Rie A, et al. False-positive rifampicin resistance on Xpert(R) MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis. 2012;16(2):206-208
11. Mokaddas E, et al. Discordance between Xpert MTB/RIF assay and Bactec MGIT 960 Culture System for detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country with a low tuberculosis (TB) incidence. J Clin Microbiol. 2015;53 (4):1351-1354
12. Sanchez-Padilla E, et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015;372(12):1181-1182
13. Koser CU, et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. Plos Pathogens. 2012;8(8):e1002824
14. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66(7):1417-1430
15. Casali N, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014;46 (3):279-286
16. Coll F, et al. Rapid determination of antituberculosis drug resistance from wholegenome sequences. Genome Med. 2015;7 (1):51
17. Zhang H, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet. 2013;45 (10):1255-1260
18. Koser CU, et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med. 2013;369 (3):290-292
19. Walker TM, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15 (10):11903-1202
20. Doughty EL, et al. Culture-independent detection and characterisation of Mycobacterium tuberculosis and M. africanum in sputum samples using shotgun metagenomics on a benchtop sequencer. PeerJ. 2014;2:e585
21. Votintseva AA, et al. Mycobacterial DNA extraction for whole-genome sequencing from early positive liquid (MGIT) cultures. J Clin Microbiol. 2015;53 (4):1137-1143
22. Tabacchioni S, et al. Bias caused by using different isolation media for assessing the genetic diversity of a natural microbial population. Microb Ecol. 2000;40 (3):169-176
23. Brown AC, et al. Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples. J Clin Microbiol. 2015;53(7):2230-2237
24. Rigouts L, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol. 2013;51(8):2641-2645
25. Van Deun A, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013;51(8):2633-2640.